Clinical trial
Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive…
NCT00080288 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00080288 |
|---|---|
| Title | Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD |
| Official title | A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Excessive Sleepiness, Shift Work Sleep Disorder |
| Intervention type | Drug |
| Interventions | Armodafinil 150 mg/day, Placebo |
| Enrollment | 254 |
| Start date | Mar 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Mar 29, 2004 |
| Last update posted | Jul 19, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: